2019
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Abello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.Peer-Reviewed Original ResearchRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaDisease-free survivalHigh-risk subsetVenous tumor thrombusTyrosine kinase inhibitorsAdjuvant settingCytoreductive nephrectomyUnresectable diseaseAdjuvant therapyAdvanced diseaseNeoadjuvant therapyOverall survivalTumor thrombusGenitourinary malignanciesPartial nephrectomySignificant causeTherapyEffective agentNephrectomyMonoclonal antibodiesKinase inhibitorsDisease
2016
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea
Cheong H, Jo S, Yoon S, Cho H, Kim J, Kim Y, Koo J, Park Y, Park Y, Shin J, Yoo K, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal Of Korean Medical Science 2016, 31: 1516-1528. PMID: 27550478, PMCID: PMC4999392, DOI: 10.3346/jkms.2016.31.10.1516.Peer-Reviewed Original ResearchConceptsAtypical hemolytic uremic syndromeHemolytic uremic syndromeUremic syndromeManagement of atypical hemolytic uremic syndromeTreatment of atypical hemolytic uremic syndromePathogenesis of atypical hemolytic uremic syndromeMicro-angiopathic hemolytic anemiaEnd-stage renal diseaseAcute kidney injuryTreatment of patientsClinical practice guidelinesThrombotic microangiopathyDelayed DiagnosisKidney injuryRare syndromeHemolytic anemiaComplement C5 activationRenal diseaseAppropriate managementEffective agentKorean populationSyndromeComplement systemLack of evidenceC5 activation
2015
dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis
Lim S, Kim WJ, Kim YH, Lee S, Koo JH, Lee JA, Yoon H, Kim DH, Park HJ, Kim HM, Lee HG, Yun Kim J, Lee JU, Hun Shin J, Kyun Kim L, Doh J, Kim H, Lee SK, Bothwell AL, Suh M, Choi JM. dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nature Communications 2015, 6: 8244. PMID: 26372309, PMCID: PMC4579786, DOI: 10.1038/ncomms9244.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisMultiple sclerosisT cellsAutoimmune encephalomyelitisCytotoxic T-lymphocyte antigen-4T-lymphocyte antigen-4T helper 17 (Th17) cellsCNS inflammatory diseasesTherapeutic mouse modelsEffector T cellsHelper 17 cellsT helper 1Blood-brain barrierCentral nervous systemHuman T cellsHelper 1Antigen-4Inflammatory diseasesMouse modelNervous systemCurrent drugsResident cellsBrain tissueEffective agentCell-permeable peptide
2013
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney P, Wood C. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2013, 155-177. DOI: 10.1007/978-1-4614-7236-0_10.Peer-Reviewed Original ResearchSystemic therapyBenefit of cytoreductionTargeted therapy eraVenous tumor thrombusRenal cell carcinomaTyrosine kinase inhibitorsAdjuvant settingUnresectable diseaseAdvanced diseaseCytoreductive surgeryNeoadjuvant therapyTherapy eraAdjuvant therapyMetastatic RCCTumor thrombusGenitourinary malignanciesCell carcinomaPartial nephrectomySurgeryTherapyEffective agentMonoclonal antibodiesKinase inhibitorsDiseaseCurrent roleAdvances in the systemic treatment of metastatic melanoma.
Yushak M, Kluger HM, Sznol M. Advances in the systemic treatment of metastatic melanoma. Oncology 2013, 27: 374-81. PMID: 25184258, PMCID: PMC6092183.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalDrug Therapy, CombinationHumansImidazolesImmunologic FactorsImmunotherapy, AdoptiveIndolesIpilimumabMelanomaMutationNivolumabOximesProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesSkin NeoplasmsSulfonamidesVemurafenibConceptsMetastatic melanomaTumor-host immune interactionsRandomized phase III trialPhase III trialsCombination of dabrafenibAdoptive cell therapyStandard of carePromising new agentPhase II dataIII trialsOverall survivalSystemic treatmentPredictive biomarkersMechanisms of resistanceTreatment outcomesIndividual patientsLimited efficacyAvailable agentsImmune interactionsNew agentsMolecular alterationsEffective agentCell therapyCurrent agentsMelanoma cells
2008
Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine
Xian Zhou, Suyu Liu, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine. Clinical Trials 2008, 5: 181-193. PMID: 18559407, PMCID: PMC5481999, DOI: 10.1177/1740774508091815.Peer-Reviewed Original ResearchConceptsDisease control rateBiomarker profilesControl rateTrial designRandomization ratesEffective agentLung cancerAdvanced stage non-small cell lung cancerStage non-small cell lung cancerNon-small cell lung cancerBaseline biopsy samplesPatient's biomarker profileCell lung cancerEarly stopping ruleEvaluable patientsPrimary endpointMore patientsPersonalized medicineAdaptive randomization designEffective treatmentBiomarker assessmentBiopsy samplesPatientsBayesian adaptive designIndividual tumorsA Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy
Norberg MM, Krystal JH, Tolin DF. A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy. Biological Psychiatry 2008, 63: 1118-1126. PMID: 18313643, DOI: 10.1016/j.biopsych.2008.01.012.Peer-Reviewed Original ResearchConceptsExposure therapyFear extinctionD-cycloserineNMDA receptor functionPartial N-methyl-d-aspartate (NMDA) receptor agonistEffects of DCsExposure-based therapyExposure-based treatmentsFear memory consolidationReceptor functionN-methyl-D-aspartate receptor agonistMemory consolidationDCS doseTranslational researchExposure procedureTherapy literatureEnglish-language journal articlesReceptor agonistQuantitative reviewTrial designMeta-analysisTherapyStudy authorsTypes of subjectsEffective agent
2007
A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine
Zhou X, Kim E, Herbst R, Liu S, Wistuba I, Mao L, Lewis J, Lippman S, Hong W, Lee J. A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine. Journal Of Clinical Oncology 2007, 25: 7697-7697. DOI: 10.1200/jco.2007.25.18_suppl.7697.Peer-Reviewed Original ResearchBiomarker profilesEffective agentResponse rateRandomization ratesLung Cancer EliminationTumor biomarker profilesClinical trial designBayesian adaptive randomizationCancer ptsPrior chemotherapyTreatment armsClinical efficacyLung cancerCancer eliminationEffective therapyLung carcinogenesisTargeted therapyDifferent biomarker profilesTrial designTreatment efficacyBiopsy samplesTherapy trialsPatient entryBiomarker expressionTherapy
2003
Buprenorphine for Opioid Detoxification
Kosten T. Buprenorphine for Opioid Detoxification. Addictive Disorders & Their Treatment 2003, 2: 107-112. DOI: 10.1097/00132576-200302040-00001.Peer-Reviewed Original ResearchPharmacotherapy of opioid dependenceRelapse prevention treatmentOpiate dependent patientsDose of buprenorphineNaltrexone adherencePsychosocial treatmentsAntagonist naltrexoneBuprenorphine withdrawalOpiate detoxificationOpioid detoxificationNaltrexoneDependent patientsOpioid dependenceDepot formDosage taperingBuprenorphinePreventive treatmentEffective agentLong durationDoseTreatmentClonidine/naltrexonePharmacotherapyMethadoneClonidine
1998
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS
Freedberg K, Paltiel A. Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. PharmacoEconomics 1998, 14: 165-173. PMID: 10186457, DOI: 10.2165/00019053-199814020-00005.Peer-Reviewed Original ResearchConceptsHIV patient careOpportunistic infectionsInfection preventionPatient careImmune system destructionSpecific opportunistic infectionsMajor opportunistic infectionNew antiretroviral therapiesQuality of lifeCost-effectiveness evaluationCost-effectiveness analysisCost effectivenessProphylaxis regimensAntiretroviral therapyHIV diseaseHIV infectionViral loadClinical guidelinesConsiderable financial strainProphylaxisClinical advancesViral replicationEffective agentInfectionHIVFluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug And Alcohol Dependence 1998, 50: 221-226. PMID: 9649975, DOI: 10.1016/s0376-8716(98)00032-5.Peer-Reviewed Original ResearchConceptsCocaine useOpioid addictsMedication effectsDepressive symptomsSignificant decreaseEffectiveness of fluoxetineSelf-reported cocaine useDrug use outcomesSubsample of subjectsFluoxetine treatmentUrine toxicologySelf-reported useDepressive disorderSevere depressionHeroin useFluoxetineEffective agentUse outcomesDepressionPlaceboSignificant differencesTreatmentSymptomsAddictsMethadone
1978
The chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply